Semler Scientific Inc. (SMLR): Price and Financial Metrics

Semler Scientific Inc. (SMLR): $25.37

1.50 (-5.58%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

A

SMLR Price/Volume Stats

Current price $25.37 52-week high $44.36
Prev. close $26.87 52-week low $19.12
Day low $24.86 Volume 131,700
Day high $26.96 Avg. volume 58,703
50-day MA $26.11 Dividend yield N/A
200-day MA $27.22 Market Cap 174.37M

SMLR Stock Price Chart Interactive Chart >

SMLR POWR Grades

  • SMLR scores best on the Quality dimension, with a Quality rank ahead of 98.48% of US stocks.
  • SMLR's strongest trending metric is Stability; it's been moving up over the last 177 days.
  • SMLR ranks lowest in Momentum; there it ranks in the 6th percentile.

SMLR Stock Summary

  • For SMLR, its debt to operating expenses ratio is greater than that reported by just 0.33% of US equities we're observing.
  • SMLR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 11.15% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, SEMLER SCIENTIFIC INC is reporting a growth rate of 41.99%; that's higher than 78.31% of US stocks.
  • Stocks that are quantitatively similar to SMLR, based on their financial statements, market capitalization, and price volatility, are OB, INTT, NVST, NTIC, and ITI.
  • Visit SMLR's SEC page to see the company's official filings. To visit the company's web site, go to www.semlerscientific.com.

SMLR Valuation Summary

  • In comparison to the median Healthcare stock, SMLR's price/sales ratio is 47.37% higher, now standing at 2.8.
  • SMLR's price/earnings ratio has moved up 24.8 over the prior 117 months.

Below are key valuation metrics over time for SMLR.

Stock Date P/S P/B P/E EV/EBIT
SMLR 2023-09-22 2.8 2.8 10.4 6.3
SMLR 2023-09-21 2.9 2.8 10.4 6.3
SMLR 2023-09-20 2.9 2.9 10.6 6.5
SMLR 2023-09-19 2.9 2.9 10.7 6.5
SMLR 2023-09-18 2.9 2.9 10.6 6.5
SMLR 2023-09-15 2.9 2.9 10.7 6.6

SMLR Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at 1314.39%.
  • The 3 year cash and equivalents growth rate now stands at 745.64%.
  • Its 5 year net income to common stockholders growth rate is now at 757.46%.
SMLR's revenue has moved up $4,139,000 over the prior 15 months.

The table below shows SMLR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 54.433 17.41 12.616
2022-06-30 54.377 17.026 13.091
2022-03-31 53.86 12.952 15.705
2021-12-31 53.027 16.056 17.222
2021-09-30 53.558 20.216 21.108
2021-06-30 50.294 16.097 21.824

SMLR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SMLR has a Quality Grade of A, ranking ahead of 95.98% of graded US stocks.
  • SMLR's asset turnover comes in at 1.347 -- ranking 8th of 186 Medical Equipment stocks.
  • FONR, ATRI, and STXS are the stocks whose asset turnover ratios are most correlated with SMLR.

The table below shows SMLR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.347 0.913 2.860
2021-03-31 1.358 0.904 2.919
2020-12-31 1.489 0.913 3.050
2020-09-30 1.634 0.908 2.764
2020-06-30 1.732 0.899 2.244
2020-03-31 2.128 0.898 2.802

SMLR Price Target

For more insight on analysts targets of SMLR, see our SMLR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $94.67 Average Broker Recommendation 1.33 (Strong Buy)

Semler Scientific Inc. (SMLR) Company Bio


Semler Scientific, Inc. develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition; and WellChec, a multi-test service platform to evaluate patients with various chronic diseases. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as organizations, including healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry; and other healthcare organizations, such as risk assessment groups and other home healthcare providers. It offers its products through salespersons and distributors. Semler Scientific, Inc. was founded in 2007 and is based in San Jose, California.


SMLR Latest News Stream


Event/Time News Detail
Loading, please wait...

SMLR Latest Social Stream


Loading social stream, please wait...

View Full SMLR Social Stream

Latest SMLR News From Around the Web

Below are the latest news stories about SEMLER SCIENTIFIC INC that investors may wish to consider to help them evaluate SMLR as an investment opportunity.

Director Eric Semler Buys 77,771 Shares of Semler Scientific Inc (SMLR)

On September 13, 2023, Director Eric Semler of Semler Scientific Inc (NASDAQ:SMLR) made a significant insider purchase, acquiring 77,771 shares of the company.

Yahoo | September 14, 2023

Semler Scientific to Present at Upcoming Investor Conference

Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced Renae Cormier, CFO, will participate in the following investor conference:

Yahoo | August 31, 2023

Semler Scientific Reports Second Quarter and First Half of 2023 Financial Results

Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the three and six months ended June 30, 2023.

Yahoo | August 10, 2023

Semler to Report Second Quarter 2023 Financial Results and Host Conference Call on August 10, 2023

Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of U.S. financial markets on Thursday, August 10, 2023. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Renae Cormi

Yahoo | July 28, 2023

Semler Scientific Announces Appointment of Chief Financial Officer, Record Quarterly Revenues and Strategic Streamlining

Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced the appointment of a chief financial officer (CFO), record quarterly revenues expected for the second quarter of 2023 and a strategic streamlining.

Yahoo | July 11, 2023

Read More 'SMLR' Stories Here

SMLR Price Returns

1-mo -7.48%
3-mo -3.13%
6-mo 9.35%
1-year -32.44%
3-year -52.13%
5-year -33.93%
YTD -23.12%
2022 -63.99%
2021 -2.50%
2020 95.83%
2019 39.53%
2018 330.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!